Galectin Therapeutics Inc.
Organization details
- Legal name
- Galectin Therapeutics Inc.
- Former names
- PRO Pharmaceuticals Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Nevada
- Headquarters city
- Norcross
- Headquarters state / province
- Georgia
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- GALT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001133416
- EIN
- 04-3562325
Board of directors
-
Benjamin Carson Sr. · DirectorSince 2023
-
Elissa J. Schwartz · DirectorSince 2023
-
Gilbert F. Amelio · DirectorSince 2023
-
Gilbert S. Omenn · DirectorSince 2023
-
Harold H. Shlevin · DirectorSince 2023
-
Henry Brem · DirectorSince 2026
-
James C. Czirr · DirectorSince 2023
-
Joel Lewis · Director · President and CEOSince 2023
-
Kary Eldred · DirectorSince 2023
-
Kevin D. Freeman · DirectorSince 2023
-
Marc Rubin · DirectorSince 2023
-
Richard A. Zordani Jr. · DirectorSince 2023
-
Richard E. Uihlein · DirectorSince 2023
Chief executives
Director election results
Annual meeting of December 3, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
96.7%
-
98.0%
-
98.2%
-
98.5%
-
98.5%
-
98.7%
-
98.8%
-
98.8%
-
98.9%
-
98.9%
Board connections
3 of this board's directors also sit on 5 other boards. 1 is in the same sector.
- via Gilbert S. Omenn
- via Benjamin Carson Sr.
-
Curis Inc. Same sectorvia Marc Rubin
- via Benjamin Carson Sr.
- via Benjamin Carson Sr.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $25,557
- 4 purchases by 2 insiders
- Sold, last 12 months
- $5,273,113
- 48 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 31, 2026 | Richard E. Uihlein Director, 10% owner | Option exercise | +31,825,235 | $3.00 | $95,475,705 |
| Jul 31, 2026 | Richard E. Uihlein Director, 10% owner | Option exercise | +2,550,932 | $4.05 | $10,331,275 |
| Jul 14, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Option exercise | +16,250 | $3.04 | $49,400 |
| Jul 14, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Open-market sale | −16,250 | $5.13 | $83,363 |
| Jun 29, 2026 | Harold H. Shlevin Director | Option exercise | +22,268 | $1.23 | $27,390 |
| Jun 29, 2026 | Harold H. Shlevin Director | Open-market sale | −22,268 | $5.04 | $112,231 |
| Jun 29, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Option exercise | +47,467 | $2.50 | $118,668 |
| Jun 29, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Open-market sale | −47,467 | $5.04 | $239,234 |
| Jun 26, 2026 | Harold H. Shlevin Director | Option exercise | +7,732 | $1.23 | $9,510 |
| Jun 26, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Option exercise | +2,037 | $2.20 | $4,481 |
| Jun 26, 2026 | Harold H. Shlevin Director | Open-market sale | −7,732 | $5.00 | $38,660 |
| Jun 26, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Open-market sale | −2,037 | $5.00 | $10,185 |
| Jun 26, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Option exercise | +2,533 | $2.50 | $6,333 |
| Jun 26, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Open-market sale | −2,533 | $5.00 | $12,665 |
| Jun 23, 2026 | Jamil Khurram Officer (Chief Medical Officer) | Option exercise | +7,557 | $1.23 | $9,295 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Galectin Therapeutics Inc.
Who is the CEO of Galectin Therapeutics Inc.?
Joel Lewis is Galectin Therapeutics Inc.'s President and CEO.
How many directors are on Galectin Therapeutics Inc.'s board?
Galectin Therapeutics Inc.'s board has 13 directors: Benjamin Carson Sr., Elissa J. Schwartz, Gilbert F. Amelio, Gilbert S. Omenn, Harold H. Shlevin, Henry Brem, James C. Czirr, Joel Lewis, Kary Eldred, Kevin D. Freeman and 3 others.
Are Galectin Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Galectin Therapeutics Inc. insiders bought $25,557 of shares in 4 purchases and sold $5.3 million of shares in 48 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="galectin-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.